Degboe Y, Sunzini F, Sood S, Bozec A, Sokolova M, Zekovic A, Mcinnes IB, Schett G, Goodyear CS (2022)
Publication Type: Journal article
Publication year: 2022
Book Volume: 61
Pages Range: 452-461
Journal Issue: 1
DOI: 10.1093/rheumatology/keab315
Objectives. Psoriatic arthritis (PsA) is associated with bone erosion and inflammation-induced bone loss, which are mediated by osteoclasts (OC) and modulated by inflammatory cytokines. Apremilast (APR) (a selective phosphodiesterase 4 inhibitor) is efficacious in PsA and acts by inhibiting cytokine production. However, there are no direct data informing whether and how APR affects osteoclast formation in humans.
APA:
Degboe, Y., Sunzini, F., Sood, S., Bozec, A., Sokolova, M., Zekovic, A.,... Goodyear, C.S. (2022). Apremilast inhibits inflammatory osteoclastogenesis. Rheumatology, 61(1), 452-461. https://doi.org/10.1093/rheumatology/keab315
MLA:
Degboe, Yannick, et al. "Apremilast inhibits inflammatory osteoclastogenesis." Rheumatology 61.1 (2022): 452-461.
BibTeX: Download